BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Tirzepatide: trial readouts and FDA decisions

3 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 9 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Eli Lilly and Company, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Hudson Biotech, Ikaria Bioscience Pty Ltd, Innovent Biologics (Suzhou) Co. Ltd., Hoffmann-La Roche, Novo Nordisk A/S. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2027-02-04 est.P2Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.NCT07521631 Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without DiabetesObesityrecruiting372
2027-02-14 est.P3Hudson BiotechNCT07481747 Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbiditiesrecruiting2539
2027-02-15 est.P1/P2Ikaria Bioscience Pty LtdNCT07245771 Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination Obesity &Amp; Overweightrecruiting104

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P3Eli Lilly and Company LLYNCT06962280 A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or OverweightType 1 Diabetes; Obesity; Overweightactive not recruiting465
2026-11 est.P3Eli Lilly and Company LLYNCT06914895 A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or OverweightType 1 Diabetes; Obesity; Overweightactive not recruiting905
2026-11 est.P3Eli Lilly and Company LLYNCT06662383 A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityObesityactive not recruiting800
2026-09-30 est.P1/P2Innovent Biologics (Suzhou) Co. Ltd.NCT07000955 Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe ObesityObesityactive not recruiting98
2026-09-03P2Hoffmann-La RocheNCT06965413 A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants WObesity; Overweight; Overweight With One Weight Related Comorbidityactive not recruiting285
2026-07-06P2Eli Lilly and Company LLYNCT05536804 A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesOverweight; Obesity; Chronic Kidney Disease; Type 2 Diabetes; T2Dcompleted134
2026-07-01P2Eli Lilly and Company LLYNCT06603571 A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight WObesity; Overweightcompleted367
2026-06-02P3Novo Nordisk A/S NVONCT06534411 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLDiabetes Mellitus, Type 2completed1023
2026-06-02P3Eli Lilly and Company LLYNCT06075667 A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesObesity; Overweightactive not recruiting160

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.